Heart Health
Heart Health
Revive
WELLBEING.
The heart beats about 100,000 times a day. It is the circulatory powerhouse, pumping oxygenated blood and circulating hormones throughout the body. A healthy heart is crucial to our healthspan and wellbeing, but when the heart is not functioning properly, the effects can be crippling.
80%
Improvement in Cardiac Function
Patients with heart disease report a 80% improvement in cardiac output and overall heart performance after regenerative treatments.
50%
Decrease in Heart Failure Progression
Clinical studies show regenerative therapies slow the progression of heart failure by 50% reducing hospitalizations and improving survival rates.
2x
Faster Recovery Post-Surgery
Patients recovering from heart surgeries experience recovery rates that are twice as fast with regenerative therapies compared to traditional methods.
65%
Increase in Exercise Tolerance
Individuals undergoing regenerative treatments report a 65% improvement in their ability to perform physical activities without fatigue or shortness of breath.
The Ultimate Solution for Heart Health
The Ultimate Solution for Heart Health
A groundbreaking solution for reversing cardiac damage and improving quality of life.
Patient Recovery Rate
88% of patients undergoing heart health treatments report improved cardiac function and vitality.
Symptom Relief Time
75% of patientsnotice a reduction in symptoms like fatigue and shortness of breath within two weeks.
Global Recommendations
90% of heart health specialists worldwide recommend Rehealth’s advanced therapies for improved outcomes.
Restore
HEART.
Reviving Heart Health
The Transformative Power of MSC Therapy
Cardiovascular disease affects over 244 million people worldwide, with heart attacks causing the loss of nearly 4 billion cardiac cells. This massive cellular loss leads to severe heart damage, decreased quality of life, and shortened lifespans. With more than 6.5 million people in the US living with heart failure, current treatments offer limited relief and fail to reverse existing cardiovascular damage.
Mesenchymal Stem Cells (MSCs) present a revolutionary solution for cardiac patients. These regenerative cells create an anti-inflammatory environment around the heart, promoting tissue regeneration, improving heart muscle function, and halting the progression of cardiac damage. MSCs also encourage new blood vessel formation, enhancing circulation and protecting cardiac cells from further degradation. By increasing ejection fraction and stimulating muscle regeneration, MSC therapy directly improves heart function and overall health.
Our precision MSC therapy goes beyond traditional treatments by addressing cardiovascular damage at the cellular level. Patients experience increased blood flow, improved heart function, and a renewed quality of life, offering hope to millions battling heart disease.
Treatment
PATIENT REPORT.
Improved Healing
Quicker Recovery
Improved Circulation
Improved Healing
Quicker Recovery
Improved Circulation
Better Sleep
Improved Mobility
Decreased Pain
Better Sleep
Improved Mobility
Decreased Pain
Mental Wellbeing
Physical Wellness
Mental Wellbeing
Physical Wellness
Experience
REAL PATIENT.
“After my stem cell treatment in Cancun, my ejection fraction improved, and I no longer felt the effects of heart failure.”
- Majka M, Sulkowski M, Badyra B, Musialek P. Concise review: mesenchymal stem cells in cardiovascular regeneration: emerging research directions and clinical applications. Stem Cells Trasl Med. 2017. 6(10):1859-67.
- Quevedo HC, Hatzistergos KE, Oskouei BM, et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trinileage differenciation capacity. Proc Natl Acad Sci USA. 2009. 106:14022-7.
- Yeo RW, Lai RC, Zhang B, et al. Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. Adv Drug Deliv Rev. 2013. 65:336-41.
- Mokarizadeh A, Delirezh N, Morshedi A, Mosayebi G, Farshid AA, Mardani K. Microvesicles derived from mesenchymal stem cells: potent organelles for induction of tolerogenic signaling. Immunol Lett. 2012. 147:47-54.
- Hubbard RE, O’Mahony MS, Savva GM, Calver BL, Woodhouse KW. Inflammation and frailty measures in older people. J Cell Mol Med. 2009. 13(9B):3103-9.
- Collerton J, Martin-Ruiz C, Davies K, et al. Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: cross-sectional findings from the Newcastle 85+ study. Mech Ageing Dev. 2012. 133(6)456-66.
- Schaap LA, Pluijm SM, Deeg DJ, et al. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol A Biol Sci Med Sci. 2009. 64(11):1183-9.
- Visser M, Pahor M, Taaffe DR, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the health ABC study. J Gerontol A Biol Sci Med Sci. 2002. 57(5):M326-32.
- Serviddio G, Romano AD, Greco A, et al. Frailty syndrome is associated with altered circulating redox balance and increased markers of oxidative stress. Int J Immunopathol Pharmacol. 2009. 22(3):819-27.
- Tay L, Lim WS, Chan M, Ye RJ, Chong MS. The independent role of inflammation in physical frailty among older adults with mild cognitive impairment and mild-to-moderate Alzheimer’s disease. J Nutr Health Aging. 2016. 20(3):288-99.
- Glenn JD, Whartenby KA. Mesenchymal stem cells: emerging mechanisms of immunomodulation and therapy. World J Stem Cells. 2014. 6(5):526-39.
- Wang S, Qu X, Zhao RC. Clinical applications of mesenchymal stem cells. J Hematol Oncol. 2012. 5:19.
- Yao X, Li H, Leng SX. Inflammation and immune system alterations in frailty. Clin Geriatr Med. 2011. 27(1):79-87.
- Premer C, Blum A, Bellio MA, et al. Allogeneic mesenchymal stem cells restore endothelial function in heart failure by stimulating endothelial progenitor cells. EBioMedicine. 2015. 2(5):467-75.
- Aso K, Tsuruhara A, Takagaki K, et al. Adipose-derived mesenchymal stem cells restore impaired mucosal immune responses in aged mice. PLoS ONE. 2016. 11(2): e0148185.
- Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999. 284(5411):143-7.
- Hodgkinson CP, Bareja A, Gomez JA, et al. Emerging concepts in paracrine mechanisms in regenerative cardiovascular medicine and biology. Circ Res. 2016. 118:95-107.
- Markel TA, Wang Y, Herrmann JL, et al. VEGF is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function. Am J Physion Heart Circ Physiol. 2008. 295:H2308-14.
- Mirotsou M, Zhang Z, Deb A, et al. Secreted fizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell released paracrine factor mediating myocardial survival and repair.
- Hatzistergos KE, Quevedo H, Oskouei BN, et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res. 2010. 107:913-22.
- Reinecke H, Minami E, Zhu WZ, et al. Cardiogenic differentiation and transdifferentiation of progenitor cells. Circ Res. 2008. 103:1058-71.
- Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics 2016 Update: A report from the American Heart Association. Circulation. 2016. 133:e38-60.
- Lu LL, Liu YJ, Yang SG, et al. Isolation and characterization of human umbilical cord mesenchymal tem cells with hematopoiesis supportive function and other potentials. Haematologica. 2006. 91(8):1017-26.
- Behjati M. Suggested indications of clinical practice guideline for stem cell therapy in cardiovascular diseases: a step wise appropiate use criteria for regeneration therapy. ARYA Atheroscler. 2013. 9(5):306-10.
- Collichia M, Jones DA, Beirne AM, et al. Umbilical cord-derived mesenchymal stromal cells in cardiovascular disease: review of preclinical and clinical data. Cytotherapy. 2019. 1-12.
Download
REHEALTH BROCHURE.